BioNTech aims to develop a more effective vaccine against malaria, one of the world's deadliest diseases. Nearly 230 million people are infected with the mosquito-borne parasite each year. The German firm is now seeking to follow up its successful COVID-19 vaccine, with a malaria jab based on the same messenger RNA technology. If successful, the shot could significantly reduce the mortality rate of the disease. Sibel Karkus has more.

#Malaria #BioNTech #mRNA